Crimson Publishers Publish With Us Reprints e-Books Video articles


Modern Applications in Pharmacy & Pharmacology

Cyclin Dependent Kinases: Old Target with New Challenges for Anti-Cancer Drugs

Submission: January 20, 2018; Published: February 07, 2018

DOI: 10.31031/MAPP.2018.01.000513

ISSN 2637-7756
Volume1 Issue3


Cyclin-dependent kinases are a family of serine or threonine protein kinases. There are various CDK Inhibitors such as Palbociclib, Abemaciclib and Ribociclib have been developed. First generation CDKIs, targeting multiple CDKs were developed but not progressed for further phase-II trials because of high toxicity and low therapeutic index. So there is urgent need to overcome this problem by developing new CDK inhibitors. This mini-review summarizes the role of CDK in cancer progression and challenges for developing new inhibitors in modern perspectives.

Keywords: DNA replication; T-loop; Chromosome; Breast cancer; US-FDA

Get access to the full text of this article